Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies
L Succony, DM Rassl, AP Barker, FM McCaughan… - Cancer treatment …, 2021 - Elsevier
Adenocarcinoma has become the most prevalent lung cancer sub-type and its frequency is
increasing. The earliest stages in the development of lung adenocarcinomas are visible …
increasing. The earliest stages in the development of lung adenocarcinomas are visible …
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like
(APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven …
(APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven …
AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer
Background The EGFR T790M mutation is the most common mechanism of drug resistance
to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have …
to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have …
Non-small-cell lung cancers: a heterogeneous set of diseases
Z Chen, CM Fillmore, PS Hammerman, CF Kim… - Nature Reviews …, 2014 - nature.com
Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have
diverse pathological features. During the past decade, in-depth analyses of lung cancer …
diverse pathological features. During the past decade, in-depth analyses of lung cancer …
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics
CL Arteaga, JA Engelman - Cancer cell, 2014 - cell.com
ERBB receptors were linked to human cancer pathogenesis approximately three decades
ago. Biomedical investigators have since developed substantial understanding of the …
ago. Biomedical investigators have since developed substantial understanding of the …
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
EA Akbay, S Koyama, J Carretero, A Altabef… - Cancer discovery, 2013 - AACR
The success in lung cancer therapy with programmed death (PD)-1 blockade suggests that
immune escape mechanisms contribute to lung tumor pathogenesis. We identified a …
immune escape mechanisms contribute to lung tumor pathogenesis. We identified a …
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a …
R Rosell, E Carcereny, R Gervais… - The lancet …, 2012 - thelancet.com
Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
[HTML][HTML] A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
SV Sharma, DY Lee, B Li, MP Quinlan, F Takahashi… - Cell, 2010 - cell.com
Accumulating evidence implicates heterogeneity within cancer cell populations in the
response to stressful exposures, including drug treatments. While modeling the acute …
response to stressful exposures, including drug treatments. While modeling the acute …
Screening for epidermal growth factor receptor mutations in lung cancer
Background Activating mutations in the epidermal growth factor receptor gene (EGFR)
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …